BioChain to Distribute Clinical Genomics' Cancer Test in China

BioChain, a diagnostics company with operations in San Francisco and China, has become the exclusive China distributor of Clinical Genomics' colorectal cancer screening technology. Clinical Genomics of Australia has marketed Insure FIT®, a fecal immunochemical test, around the globe since 1994. BioChain, which will run a China trial of the test to qualify for CFDA approval, will attempt to make the test part of China's recently announced Cancer Screening Feasibility Study. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.